Company / SG&A Expense
Immunocore Holdings plc SG&A Expense History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$165.4M
FY2025
5-year range
$110.8M / $165.4M
FY2021-FY2025
Trend
+6.2%
vs FY2024
Sector context
#85 of 213
Health Care
What the data says
At $165M, Immunocore Holdings plc's sg&a expense ranks #129 of 213 in the Health Care sector. SG&A Expense has increased for 4 consecutive years, from $111M in FY2021 to $165M in FY2025.
Based on SEC 10-K filings.
$165M in FY2025 with a 3-year CAGR of +10.4%.
Increased from $144M to $165M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +10.4%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#129 of 213 in Health CareTop 60% of 213This company $165.4M Sector average $722.3M
▼
-77.1% below sector average
Key checks
Key Insights
- Immunocore Holdings plc's sg&a expense has grown for 4 consecutive years.
- 3-year CAGR of +10.4%, indicating consistent growth.
- In FY2025, sg&a expense increased 6.2% year-over-year.
- Ranks #85 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 0.32 (distress zone, below 1.8 threshold)
- Negative profit margin: -16.5%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $165.4M | +6.2% |
| FY2024 | $155.8M | +7.8% |
| FY2023 | $144.5M | +17.4% |
| FY2022 | $123.1M | +11.0% |
| FY2021 | $110.8M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026